A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome


The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double


  • Drug: Lopinavir / Ritonavir plus Ribavirin

Clinical Trial Outcome Measures

Primary Measures

  • Development of severe SARS
    • Time Frame: Any time during the acute illness

Secondary Measures

  • Adverse events
    • Time Frame: Throughout the illness period
  • SARS-CoV Viral load
    • Time Frame: Throughout the illness period
  • Immunological profile
    • Time Frame: Throughout the illness period

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited. Exclusion Criteria:

  • Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Hospital Authority, Hong Kong
  • Overall Official(s)
    • Wai Cho Yu, Dr, Principal Investigator, Department of Medicine & Geriatrics, Princess Margaret Hospital
  • Overall Contact(s)
    • Wai Cho Yu, Dr, (852) 2990 3737, yuwc@ha.org.hk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.